Metagenomi, Inc. is a precision genetic medicine company. The Company is focused on developing curative therapeutics for patients using its comprehensive metagenomics derived toolbox. Its diverse and modular genome editing toolbox is designed to precisely target any site in the human genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs). It has also developed a modular toolbox of genome editing systems that will allow it to interact with the human genome in a site-specific manner, where each tool can be matched to specific disease targets. The Company uses artificial intelligence and its metagenomics platform to develop curative genetic medicines.
Growing
The company is in a growing phase, with the latest annual income totaling USD 25.21M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 25.21M.
Overvalued
The company’s latest PE is -0.55, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 8.82M shares, decreasing 42.09% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 11.64K shares of this stock.